Skip to main content
Premium Trial:

Request an Annual Quote

Aclara Licenses eTag System to Tokyo Medical Science Institute

NEW YORK (GenomeWeb News) Oct. 1 - Aclara Biosciences of Mountain View, Calif., has signed an agreement to provide Rinshoken, the Tokyo Metropolitan Institute of Medical Science, with access to its eTag Assay system, the company said today.

 

TMIMS researcher Futoshi Shibasaki will use the system to develop multiplexed assays for hypoxia-inducible factors in cells and tissues, which occur in heart attack, stroke, and other cerebrovascular disorders, according to Aclara. Shibasaki's laboratory studies the way gene expression is modulated by hypoxic responsive factors, in an effort to discover diagnostic and therapeutic targets in this area.

 

The license also includes access to the reagent products, the software, and support for the system.

"We would like to analyze specific proteins for their dependence on HIFs under several experimental conditions that mimic disease situations, Futoshi Shibasaki, director of the Molecular Cell Physiology Laboratory at TMIMS, said in a statement. "Moreover, these types of assays could be valuable for diagnosis and patient stratification in cancer."

 

This is Aclara's first deal with a Japanese research organization.

The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.